文献速递神经肿瘤神经重症

松果体转移瘤的立体定向放射外科治疗:国际放射外科研究基金会结果

Stereotactic radiosurgery for pineal gland metastases: results from the international radiosurgery research foundation.
PubMed 文献 · J Neurooncol · 2026-01-29

本研究为多机构回顾性研究,纳入26例松果体转移瘤患者接受立体定向放射外科(SRS)治疗。中位处方剂量18 Gy单次,中位随访9个月,局部肿瘤控制(LC)在3、6、12、24个月分别为100%、94.4%、87.7%、87.7%,中位总生存32个月,无SRS后脑积水发生。

要点

  • SRS对松果体转移瘤局部控制率高,24个月LC达87.7%。
  • 基线有症状的13例中7例改善、6例稳定,症状改善率高。
  • 远处肿瘤控制有限,24个月DC仅35.2%。

核心结论

  • SRS对松果体转移瘤提供优异的局部肿瘤控制,症状改善率高,软脑膜播散率低,SRS后并发症有限。
  • 尽管局部控制良好,远处肿瘤控制在此 setting 中有限,可能通过改善全身疾病管理来提高。

研究设计与样本

  • 多机构回顾性研究,纳入国际放射外科研究基金会(IRRF)治疗中心接受SRS的松果体区域转移瘤患者。
  • 共26例患者(16例女性,62%),中位年龄60岁(范围16–87),26个松果体转移灶。

主要发现

  • 原发肿瘤组织学为肺(46.2%)、乳腺(26.9%)、黑色素瘤(7.7%)和其他(19.2%)。
  • SRS治疗在多数病例中为 upfront(61.5%),辅助(19.2%)或挽救(19.2%)。
  • 中位处方剂量为18 Gy单次分割。
  • 中位随访9个月(范围3–101)。
  • 局部肿瘤控制(LC)在3、6、12、24个月分别为100%、94.4%、87.7%、87.7%;远处肿瘤控制(DC)在相同间隔分别为79.2%、73.9%、52.8%、35.2%。

关键数值与推荐

  • 中位处方剂量18 Gy单次分割。
  • LC在3、6、12、24个月分别为100%、94.4%、87.7%、87.7%。
  • DC在3、6、12、24个月分别为79.2%、73.9%、52.8%、35.2%。
  • 中位OS为32个月(范围6–52)。
  • AREs发生率53.8%,中位发生时间4个月;软脑膜播散7.7%,无SRS后脑积水。

临床怎么用

  • SRS可作为松果体转移瘤的有效局部治疗选择,尤其适用于手术高风险患者。
  • 治疗前存在症状的患者可能从SRS中获得症状改善。
  • 需关注远处肿瘤控制,应结合全身疾病管理。
  • AREs发生率较高,需在随访中监测。

局限性

  • 回顾性研究设计。
  • 样本量小(26例)。
  • 中位随访时间较短(9个月)。
  • 未评估的 prognostic factors 未发现与LC、DC或OS显著相关。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Metastases to the pineal gland are rare. Surgical excision can be associated with high rates of morbidity. Alternatively, stereotactic radiosurgery (SRS) for brain metastases in the pineal region has not been vigorously studied. METHODS: We performed a multi-institutional retrospective study for patients treated with SRS for pineal region metastases at treatment centers that comprise the International Radiosurgery Research Foundation (IRRF). Demographics, tumor characteristics, treatment parameters, and clinical outcomes were collected. The primary endpoint was local tumor control (LC). Secondary endpoints included: Overall survival (OS), distant tumor control (DC), and adverse radiation events (AREs). Kaplan-Meier and Cox regression analyses were performed to evaluate time to event endpoints and prognostic factors respectively. RESULTS: Twenty-six patients (16 female, 62% median age 60 years (range: 16–87) with 26 pineal metastases were managed with SRS. Primary tumor histology was lung (46.2%), breast (26.9%), melanoma (7.7%), and other (19.2%). SRS treatment was up-front in the majority of cases (61.5%), adjuvant (19.2%) or salvage therapy (19.2%). The median prescription dose was 18 Gy in a single fraction. Median follow-up was 9 months (range 3–101). LC at 3-,6-,12-, and 24-months was 100%, 94.4%, 87.7%, and 87.7% respectively. DC at the same intervals were 79.2%, 73.9%, 52.8%, and 35.2%. Median OS was 32 months (range: 6–52). No evaluated prognostic factors were significantly associated with LC, DC, or OS. Among the 13 patients with symptoms related to their pineal tumor at baseline, 7 improved and 6 remained stable following SRS. Leptomeningeal spread occurred in 7.7% of patients and no cases of post-SRS hydrocephalus were observed. Overall AREs occurred in 14 (53.8%) patients, with a median time to onset of 4 months. CONCLUSION: SRS offers excellent local tumor control of pineal metastases with high rates of symptomatic improvement, minimal leptomeningeal spread, and limited post-SRS complications. Despite this, distant tumor control is limited in this setting and may be improved by improved systemic disease management.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Kite T, Mckenna A, Wegner RE, et al. Stereotactic radiosurgery for pineal gland metastases: results from the international radiosurgery research foundation. J Neurooncol. 2026. PMID: 41609888. doi:10.1007/s11060-026-05432-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。